Literature DB >> 8225037

Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy.

D L Gustafson1, J D Swanson, C A Pritsos.   

Abstract

The toxicity of the antineoplastic agent doxorubicin (DOX) has been shown to be moderated by the antioxidant enzyme glutathione peroxidase. It has been reported that acute doses of DOX can cause an inhibition of glutathione peroxidase in cardiac tissue, that may render this tissue especially susceptible to further prooxidant damage. In this study, multiple DOX treatments at a therapeutic dose were assessed for their effect on the antioxidant enzyme status of cardiac and kidney tissue. DOX was administered i.p. (5 mg/kg) once a week for two weeks to male balb/c mice. The activities of the antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPOX) and glutathione reductase (GR) were measured 1, 2 and 7 days following the second DOX treatment in both heart and kidney. Levels of reduced glutathione (GSH) were also measured in cardiac tissue at these same times. Cardiac levels of GPOX and GR showed a time-dependent decrease in activity, with 10% and 12% inhibition for GPOX and GR, respectively, at 7 days post second treatment. Cardiac levels of GSH also showed a significant decrease, approximately 15%, at 7 days post second treatment. Cardiac levels of SOD and CAT as well as kidney levels of all four antioxidant enzymes were not affected by DOX treatment. These data suggest that DOX given in a therapeutic regimen, at a therapeutic dose, can cause decreases in cardiac levels of GPOX, GR and GSH that could render the heart especially susceptible to further oxidative challenge.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225037     DOI: 10.3109/10715769309056505

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  5 in total

Review 1.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

2.  The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.

Authors:  Agnieszka Korga; Jaroslaw Dudka; Franciszek Burdan; Justyna Sliwinska; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-02-26       Impact factor: 6.543

3.  A low dose of doxorubicin improves antioxidant defence system and modulates anaerobic metabolism during the development of lymphoma.

Authors:  Nibha Verma; Manjula Vinayak
Journal:  Indian J Pharmacol       Date:  2012-05       Impact factor: 1.200

4.  Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.

Authors:  Justyna Sliwinska; Jaroslaw Dudka; Agnieszka Korga; Franciszek Burdan; Wlodzimierz Matysiak; Barbara Jodlowska-Jedrych; Slawomir Mandziuk; Katarzyna Dawidek-Pietryka
Journal:  Oxid Med Cell Longev       Date:  2012-05-15       Impact factor: 6.543

Review 5.  Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation.

Authors:  Xiaoli Tang; Zengwu Wang; Shengshou Hu; Bingying Zhou
Journal:  Pharmaceutics       Date:  2022-06-21       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.